Cytokinetics Inc. (CYTK) is a publicly traded Healthcare sector company. As of May 21, 2026, CYTK trades at $78.84 with a market cap of $10.21B and a P/E ratio of -11.44. CYTK moved +2.97% today. Year to date, CYTK is +28.58%; over the trailing twelve months it is +141.18%. Its 52-week range spans $29.31 to $80.20. Analyst consensus is strong buy with an average price target of $100.18. Rallies surfaces CYTK's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Which politicians traded CYTK stock?
Recent politician trading activity in CYTK includes disclosures from Lisa McClain. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
CYTK Key Metrics
Key financial metrics for CYTK
Metric
Value
Price
$78.84
Market Cap
$10.21B
P/E Ratio
-11.44
EPS
$-6.84
Dividend Yield
0.00%
52-Week High
$80.20
52-Week Low
$29.31
Volume
308
Avg Volume
0
Revenue (TTM)
$105.81M
Net Income
$-829.61M
Gross Margin
0.00%
Congressional Trades in CYTK
Lisa McClain purchase CYTK on Jun 11, 2025 (amount: $15.00K) for Spouse.
Recent politician trading activity in CYTK includes disclosures from Lisa McClain. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
Does Rallies track congressional trades in CYTK?
Yes. Rallies tracks politician and congressional stock disclosures for CYTK, including reported purchases, sales, dates, owners, and trade amounts when available.
Is CYTK research on Rallies investment advice?
No. Rallies provides research, data, and educational context for CYTK. It does not provide personalized investment advice.
